|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
University of British Columbia |
| Information provided by: | University of British Columbia |
| ClinicalTrials.gov Identifier: | NCT00247806 |
Purpose
It is currently assumed that all patients are lactose intolerant post bone marrow transplantation. This pilot study is to assess what the incidence of lactose intolerance is after bone marrow transplantation in children. This will be done using a lactose breath test.
| Condition | Phase |
|
Lactose Intolerance |
Phase I |
| MedlinePlus related topics: | Lactose Intolerance |
| ChemIDplus related topics: | Lactose |
| Study Type: | Observational |
| Study Design: | Screening, Cross-Sectional, Defined Population, Prospective Study |
| Official Title: | Prevalence of Lactose Intolerance Following Stem Cell Transplantation in Pediatric Patients. |
| Estimated Enrollment: | 20 |
| Study Start Date: | October 2005 |
| Estimated Study Completion Date: | October 2006 |
All pediatric patients over the age of 4 years who are scheduled for a stem cell transplant will be approached to assess whether what the incidence of lactose intolerance is in the post transplant period and how quickly recovery occurs. A baseline lactose and lactulose breath test will be performed followed by repeat lactose breath tests starting 2 weeks after day 0 and repeated every fortnight for 10 weeks. Stool pH and reducing substances will be checked at the time of the breath tests to see if there is any correlation.
Eligibility
| Ages Eligible for Study: | 4 Years to 18 Years |
| Genders Eligible for Study: | Both |
Inclusion Criteria:
All patients planned to undergo a stem cell transplant.
Exclusion Criteria:
refusal to participate, Unable to perform breath tests on request (generally under the age of 4 years.).
Contacts and Locations| Contact: Colin C Barker | cbarker@cw.bc.ca |
| Canada, British Columbia | |||||
| BC Children’s Hospital | Not yet recruiting | ||||
| Vancouver, British Columbia, Canada, V6H 3V4 | |||||
| Contact: Colin C Barker, PhD cbarker@cw.bc.ca | |||||
| Principal Investigator: Colin C Barker, PhD | |||||
| University of British Columbia |
| Principal Investigator: | Colin Barker, PhD | University of British Columbia |
More Information
| Study ID Numbers: | C05-0180 |
| First Received: | October 31, 2005 |
| Last Updated: | October 31, 2005 |
| ClinicalTrials.gov Identifier: | NCT00247806 |
| Health Authority: | Canada: Health Canada |
|
|
|
|